Last edition
News about Market
Sobi has acquired Arthrosi Therapeutics, adding phase III gout candidate pozdeutinurad (AR882) to its portfolio, with trial results expected in 2026.
Market | 11/02/2026 | By News Bureau | 164
GSK's RSV Vaccine Arexvy Accepted for Regulatory Review in China for Adults Aged 60 and Above
China’s drug regulator has accepted GSK’s Arexvy for review to prevent RSV-related lower respiratory tract disease in adults 60 and older, with a decision expected in 2027.
Market | 11/02/2026 | By News Bureau | 185
Lupin Resolves Mirabegron Patent Dispute with Astellas in USD 90 Million Settlement
Lupin Limited has reached a USD 90 million settlement to resolve a patent dispute with Japan-based Astellas Pharma concerning Lupin’s generic version of mirabegron, a treatment for overactive bladder. The agreement concludes ongoing litigation in the United States and provides commercial clarity around Lupin’s continued participation in the market.
Market | 11/02/2026 | By Darshana | 140
Pandorum Technologies Raises USD 18 Million in Series B to Advance Regenerative Therapies
Pandorum Technologies has raised USD 18 million in a Series B funding round to accelerate the clinical development and global market access of its programmable tissue regenerative therapies, with expansion plans spanning the US, Asia and the Middle East.
Market | 11/02/2026 | By News Bureau | 150
Waters Completes Merger with BD's Biosciences and Diagnostic Solutions Businesses
Waters has completed its merger with BD’s Biosciences and Diagnostic Solutions businesses, creating a global life sciences and diagnostics leader focused on high-volume testing in regulated applications, alongside announcing the appointment of Claire M Fraser, PhD, to its Board and the formation of four new operating divisions.
Market | 10/02/2026 | By News Bureau | 177
Novartis Builds Global Biomedical Research Centre in San Diego
Novartis launches construction of a 466,000-square-foot biomedical research centre in San Diego, set to open in 2029, strengthening global drug discovery and advancing neuroscience, oncology and next-generation therapies.
Market | 09/02/2026 | By News Bureau | 120
Innovent Collaborates with Lilly to Develop New Medicines in Oncology and Immunology
The agreement grants Lilly an exclusive licence to develop and commercialise the programmes worldwide outside Greater China, while Innovent retains rights in Greater China.
Market | 09/02/2026 | By News Bureau | 101
Breckenridge Pharmaceutical enters a strategic collaboration with Medichem Solutions to supply injectable medicines for anaesthesia, critical care and emergency use, strengthening its presence in the US hospital segment.
Market | 07/02/2026 | By News Bureau | 144
Angitia Biopharmaceuticals Bags USD 130 Million in Series D Capital Raise
Angitia Biopharmaceuticals has raised USD 130 million in a Series D financing round co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners. The funds will be used to advance the clinical development of lead programmes AGA2118, AGA2115, AGA111 and other pipeline assets.
Market | 06/02/2026 | By News Bureau | 253
Insilico Medicine Receives USD 5 Million from Menarini
Insilico received an additional $5 million milestone from Menarini following first-in-patient dosing in a Phase I trial of MEN2501, a generative AI-designed KIF18A inhibitor for chromosomally unstable solid tumours.
Market | 05/02/2026 | By News Bureau | 123
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy